Vilazodone is an SSRI that Does Not Affect Sexual Function

Vilazodone is an SSRI that Does Not Affect Sexual Function

Major Depressive DisorderVilazodone is in a class of medications called selective serotonin reuptake inhibitors, or SSRIs, and is also a 5HT1A receptor partial agonist. Known as the brand name Viibryd, this medication was approved in January of 2011 to treat Major Depressive Disorder in adults. In safety studies involving 2,177 patients the most common adverse side effects were diarrhea, insomnia, nausea and vomiting. Vilazodone is available in 10, 20, and 40 milligram and the recommended dose is 40 mg once daily. Titration of this dose is suggested, beginning an initial dose of 10 mg once daily for 7 days, followed by 20 mg once daily for an additional 7 days, and then finally increased to 40 mg once daily. Marketed by Forest Pharmaceuticals this antidepressant is best taken with food to achieve adequate drug concentrations.

While there appears to be a large enough variety of antidepressants on the market, the need for different and unique treatments is clearly evident. Many patients have not found success with current therapies, or they desire newer medications that have less adverse effects. For example, vilazodone has minimal effects on sexual function. This is a pertinent issue for many patients taking antidepressants because a large majority of these drugs cause or worsen sexual dysfunction. Patients in clinical trials reported side effects regarding sexual dysfunction at a similar rate of those patients who received the placebo.

Two published eight-week Phase III trials which were comprised of 878 adults with major depressive disorder, vilazodone use was found to yield significant symptomatic improvements. Determined by mean changes from baseline in scores on the Hamilton Depression Rating Scale and other widely used clinical assessment instruments, patients who were dosed with vilazodone versus a placebo displayed optimum symptom improvement.

LGM Pharma supplies Vilazodone CAS# 163521-12-8 and Vilazodone Hydrochloride CAS# 163521-08-2 for your research and development needs. Clients can rely on LGM Pharma to provide API products alongside comprehensive support throughout the entire research and development process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.


  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service